Amylin activates distributed CNS nuclei to control energy balance

Physiology and Behavior

Volumn 136, Issue , 2014, Pages 39-46

  Mietlicki Baase, Elizabeth G ^a   Hayes, Matthew R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

IAPP; Obesity; Pramlintide; Reward; VTA

Indexed keywords

AMYLIN; AMYLIN RECEPTOR; AMYLIN RECEPTOR AGONIST; ANTIOBESITY AGENT; CALCITONIN RECEPTOR; CATECHOLAMINE; HISTAMINE; LEPTIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ARCUATE NUCLEUS; AREA POSTREMA; BRAIN NUCLEUS; CENTRAL NERVOUS SYSTEM; ENERGY BALANCE; FOOD INTAKE; IMMUNOREACTIVITY; INTRACELLULAR SIGNALING; LATERAL HYPOTHALAMUS; NONHUMAN; NUCLEUS ACCUMBENS; OBESITY; PROTEIN BINDING; REVIEW; REWARD; SIGNAL TRANSDUCTION; WEIGHT GAIN; ANIMAL; EATING; ENERGY METABOLISM; HUMAN; METABOLISM; PHYSIOLOGY;

ANIMALS; APPETITE REGULATION; CENTRAL NERVOUS SYSTEM; EATING; ENERGY METABOLISM; HUMANS; ISLET AMYLOID POLYPEPTIDE; OBESITY;

EID: 84916934842     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2014.01.013     Document Type: Review

References (122)

1. Ogawa A., Harris V., McCorkle S.K., Unger R.H., Luskey K.L. Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J Clin Invest 1990, 85:973-976.
2. Lutz T.A. The role of amylin in the control of energy homeostasis. Am J Physiol Regul Integr Comp Physiol 2010, 298:R1475-R1484.
3. Lutz T.A. Roles of amylin in satiation, adiposity and brain development. Forum Nutr 2010, 63:64-74.
4. Younk L.M., Mikeladze M., Davis S.N. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother 2011, 12:1439-1451.
5. Singh-Franco D., Robles G., Gazze D. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 2007, 29:535-562.
6. Chapman I., Parker B., Doran S., Feinle-Bisset C., Wishart J., Lush C.W., et al. Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects. Obesity 2007, 15:1179-1186.
7. Lutz T.A. Amylinergic control of food intake. Physiol Behav 2006, 89:465-471.
8. Potes C.S., Lutz T.A. Brainstem mechanisms of amylin-induced anorexia. Physiol Behav 2010, 100:511-518.
9. Grill H.J., Kaplan J.M. The neuroanatomical axis for control of energy balance. Front Neuroendocrinol 2002, 23:2-40.
10. Grill H.J. Production and regulation of ingestive consummatory behavior in the chronic decerebrate rat. Brain Res Bull 1980, 5:79-87.
11. Beaumont K., Kenney M.A., Young A.A., Rink T.J. High affinity amylin binding sites in rat brain. Mol Pharmacol 1993, 44:493-497.
12. Hilton J.M., Chai S.Y., Sexton P.M. In vitro autoradiographic localization of the calcitonin receptor isoforms, C1a and C1b, in rat brain. Neuroscience 1995, 69:1223-1237.
13. Paxinos G., Chai S.Y., Christopoulos G., Huang X.F., Toga A.W., Wang H.Q., et al. In vitro autoradiographic localization of calcitonin and amylin binding sites in monkey brain. J Chem Neuroanat 2004, 27:217-236.
14. Skofitsch G., Wimalawansa S.J., Jacobowitz D.M., Gubisch W. Comparative immunohistochemical distribution of amylin-like and calcitonin gene related peptide like immunoreactivity in the rat central nervous system. Can J Physiol Pharmacol 1995, 73:945-956.
15. Banks W.A., Kastin A.J. Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides 1998, 19:883-889.
16. Mietlicki-Baase E.G., Rupprecht L.E., Olivos D.R., Zimmer D.J., Alter M.D., Pierce R.C., et al. Amylin receptor signaling in the ventral tegmental area is physiologically relevant for the control of food intake. Neuropsychopharmacology 2013, 38:1685-1697.
17. Riediger T., Zuend D., Becskei C., Lutz T.A. The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis. Am J Physiol Regul Integr Comp Physiol 2004, 286:R114-R122.
18. Mollet A., Meier S., Riediger T., Lutz T.A. Histamine H1 receptors in the ventromedial hypothalamus mediate the anorectic action of the pancreatic hormone amylin. Peptides 2003, 24:155-158.
19. Roth J.D., Hughes H., Kendall E., Baron A.D., Anderson C.M. Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 2006, 147:5855-5864.
20. Chance W.T., Balasubramaniam A., Zhang F.S., Wimalawansa S.J., Fischer J.E. Anorexia following the intrahypothalamic administration of amylin. Brain Res 1991, 539:352-354.
21. Narayanan N.S., Guarnieri D.J., DiLeone R.J. Metabolic hormones, dopamine circuits, and feeding. Front Neuroendocrinol 2010, 31:104-112.
22. Vucetic Z., Reyes T.M. Central dopaminergic circuitry controlling food intake and reward: implications for the regulation of obesity. Wiley Interdiscip Rev Syst Biol Med 2010, 2:577-593.
23. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 1998, 80:1-27.
24. Albrandt K., Mull E., Brady E.M., Herich J., Moore C.X., Beaumont K. Molecular cloning of two receptors from rat brain with high affinity for salmon calcitonin. FEBS Lett 1993, 325:225-232.
25. Kuestner R.E., Elrod R.D., Grant F.J., Hagen F.S., Kuijper J.L., Matthewes S.L., et al. Cloning and characterization of an abundant subtype of the human calcitonin receptor. Mol Pharmacol 1994, 46:246-255.
26. Young A. Receptor pharmacology. Adv Pharmacol 2005, 52:47-65.
27. Morfis M., Tilakaratne N., Furness S.G., Christopoulos G., Werry T.D., Christopoulos A., et al. Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors. Endocrinology 2008, 149:5423-5431.
28. Tilakaratne N., Christopoulos G., Zumpe E.T., Foord S.M., Sexton P.M. Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. J Pharmacol Exp Ther 2000, 294:61-72.
29. McLatchie L.M., Fraser N.J., Main M.J., Wise A., Brown J., Thompson N., et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998, 393:333-339.
30. Hay D.L., Christopoulos G., Christopoulos A., Sexton P.M. Amylin receptors: molecular composition and pharmacology. Biochem Soc Trans 2004, 32:865-867.
31. Christopoulos G., Perry K.J., Morfis M., Tilakaratne N., Gao Y., Fraser N.J., et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 1999, 56:235-242.
32. Houssami S., Findlay D.M., Brady C.L., Myers D.E., Martin T.J., Sexton P.M. Isoforms of the rat calcitonin receptor: consequences for ligand binding and signal transduction. Endocrinology 1994, 135:183-190.
33. Bailey R.J., Walker C.S., Ferner A.H., Loomes K.M., Prijic G., Halim A., et al. Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes. Br J Pharmacol 2012, 166:151-167.
34. Gingell J.J., Burns E.R., Hay D.L. Activity of pramlintide, rat and human amylin but not Abeta1-42 at human amylin receptors. Endocrinology 2013, 155:21-26.
35. Riediger T., Schmid H.A., Lutz T., Simon E. Amylin potently activates AP neurons possibly via formation of the excitatory second messenger cGMP. Am J Physiol Regul Integr Comp Physiol 2001, 281:R1833-R1843.
36. Pierce K.L., Premont R.T., Lefkowitz R.J. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002, 3:639-650.
37. Oliver K.R., Kane S.A., Salvatore C.A., Mallee J.J., Kinsey A.M., Koblan K.S., et al. Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat. Eur J Neurosci 2001, 14:618-628.
38. Martin T.J., Findlay D.M., Houssami S., Ikegame M., Rakopoulos M., Moseley J.M., et al. Heterogeneity of the calcitonin receptor: functional aspects in osteoclasts and other sites. J Nutr 1995, 125:2009S-2014S.
39. Hay D.L., Christopoulos G., Christopoulos A., Poyner D.R., Sexton P.M. Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. Mol Pharmacol 2005, 67:1655-1665.
40. Sexton P.M., Paxinos G., Kenney M.A., Wookey P.J., Beaumont K. In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 1994, 62:553-567.
41. Christopoulos G., Paxinos G., Huang X.F., Beaumont K., Toga A.W., Sexton P.M. Comparative distribution of receptors for amylin and the related peptides calcitonin gene related peptide and calcitonin in rat and monkey brain. Can J Physiol Pharmacol 1995, 73:1037-1041.
42. Barth S.W., Riediger T., Lutz T.A., Rechkemmer G. Peripheral amylin activates circumventricular organs expressing calcitonin receptor a/b subtypes and receptor-activity modifying proteins in the rat. Brain Res 2004, 997:97-102.
43. Lutz T.A., Del Prete E., Scharrer E. Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin. Peptides 1995, 16:457-462.
44. Lutz T.A., Althaus J., Rossi R., Scharrer E. Anorectic effect of amylin is not transmitted by capsaicin-sensitive nerve fibers. Am J Physiol 1998, 274:R1777-R1782.
45. Mollet A., Gilg S., Riediger T., Lutz T.A. Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats. Physiol Behav 2004, 81:149-155.
46. Rowland N.E., Crews E.C., Gentry R.M. Comparison of Fos induced in rat brain by GLP-1 and amylin. Regul Pept 1997, 71:171-174.
47. Lutz T.A., Senn M., Althaus J., Del Prete E., Ehrensperger F., Scharrer E. Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats. Peptides 1998, 19:309-317.
48. Mack C.M., Soares C.J., Wilson J.K., Athanacio J.R., Turek V.F., Trevaskis J.L., et al. Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight. Int J Obes 2010, 34:385-395.
49. Lutz T.A., Mollet A., Rushing P.A., Riediger T., Scharrer E. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int J Obes Relat Metab Disord 2001, 25:1005-1011.
50. Llewellyn-Smith I.J., Reimann F., Gribble F.M., Trapp S. Preproglucagon neurons project widely to autonomic control areas in the mouse brain. Neuroscience 2011, 180:111-121.
51. Funahashi M., Mitoh Y., Akaike T., Matsuo R. Variety of morphological and electrophysiological properties of area postrema neurons in adult rat brain slices. Neurosci Res 2006, 54:43-48.
52. Cai Y., Hay M., Bishop V.S. Synaptic connections and interactions between area postrema and nucleus tractus solitarius. Brain Res 1996, 724:121-124.
53. Grill H.J., Hayes M.R. The nucleus tractus solitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake. Int J Obes 2009, 33(Suppl. 1):S11-S15.
54. Grill H.J., Hayes M.R. Hindbrain neurons as an essential hub in the neuroanatomically distributed control of energy balance. Cell Metab 2012, 16:296-309.
55. Potes C.S., Turek V.F., Cole R.L., Vu C., Roland B.L., Roth J.D., et al. Noradrenergic neurons of the area postrema mediate amylin's hypophagic action. Am J Physiol Regul Integr Comp Physiol 2010, 299:R623-R631.
56. Chance W.T., Balasubramaniam A., Chen X., Fischer J.E. Tests of adipsia and conditioned taste aversion following the intrahypothalamic injection of amylin. Peptides 1992, 13:961-964.
57. Barth S.W., Riediger T., Lutz T.A., Rechkemmer G. Differential effects of amylin and salmon calcitonin on neuropeptide gene expression in the lateral hypothalamic area and the arcuate nucleus of the rat. Neurosci Lett 2003, 341:131-134.
58. Potes C.S., Lutz T.A., Riediger T. Identification of central projections from amylin-activated neurons to the lateral hypothalamus. Brain Res 2010, 1334:31-44.
59. Becskei C., Riediger T., Zund D., Wookey P., Lutz T.A. Immunohistochemical mapping of calcitonin receptors in the adult rat brain. Brain Res 2004, 1030:221-233.
60. Kelley A.E. Functional specificity of ventral striatal compartments in appetitive behaviors. Ann N Y Acad Sci 1999, 877:71-90.
61. Baldo B.A., Kelley A.E. Amylin infusion into rat nucleus accumbens potently depresses motor activity and ingestive behavior. Am J Physiol Regul Integr Comp Physiol 2001, 281:R1232-R1242.
62. Fulton S., Pissios P., Manchon R.P., Stiles L., Frank L., Pothos E.N., et al. Leptin regulation of the mesoaccumbens dopamine pathway. Neuron 2006, 51:811-822.
63. Hommel J.D., Trinko R., Sears R.M., Georgescu D., Liu Z.W., Gao X.B., et al. Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron 2006, 51:801-810.
64. Alhadeff A.L., Rupprecht L.E., Hayes M.R. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 2012, 153:647-658.
65. Mietlicki-Baase E.G., Ortinski P.I., Rupprecht L.E., Olivos D.R., Alhadeff A.L., Pierce R.C., et al. The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA/kainate receptors. Am J Physiol Endocrinol Metab 2013, 305:E1367-E1374.
66. Dickson S.L., Shirazi R.H., Hansson C., Bergquist F., Nissbrandt H., Skibicka K.P. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J Neurosci 2012, 32:4812-4820.
67. Naleid A.M., Grace M.K., Cummings D.E., Levine A.S. Ghrelin induces feeding in the mesolimbic reward pathway between the ventral tegmental area and the nucleus accumbens. Peptides 2005, 26:2274-2279.
68. Egecioglu E., Jerlhag E., Salome N., Skibicka K.P., Haage D., Bohlooly Y.M., et al. Ghrelin increases intake of rewarding food in rodents. Addict Biol 2010, 15:304-311.
69. Lutz T.A., Geary N., Szabady M.M., Del Prete E., Scharrer E. Amylin decreases meal size in rats. Physiol Behav 1995, 58:1197-1202.
70. Clementi G., Busa L., de Bernardis E., Prato A., Drago F. Effects of centrally injected amylin on sexually behavior of male rats. Peptides 1999, 20:379-382.
71. Banks W.A., Kastin A.J., Maness L.M., Huang W., Jaspan J.B. Permeability of the blood-brain barrier to amylin. Life Sci 1995, 57:1993-2001.
72. Ferrier G.J., Pierson A.M., Jones P.M., Bloom S.R., Girgis S.I., Legon S. Expression of the rat amylin (IAPP/DAP) gene. J Mol Endocrinol 1989, 3:R1-R4.
73. Mulder H., Lindh A.C., Ekblad E., Westermark P., Sundler F. Islet amyloid polypeptide is expressed in endocrine cells of the gastric mucosa in the rat and mouse. Gastroenterology 1994, 107:712-719.
74. Mulder H., Leckstrom A., Uddman R., Ekblad E., Westermark P., Sundler F. Islet amyloid polypeptide (amylin) is expressed in sensory neurons. J Neurosci 1995, 15:7625-7632.
75. Dobolyi A. Central amylin expression and its induction in rat dams. J Neurochem 2009, 111:1490-1500.
76. Szabo E.R., Cservenak M., Dobolyi A. Amylin is a novel neuropeptide with potential maternal functions in the rat. FASEB J 2012, 26:272-281.
77. Villanueva E.C., Myers M.G. Leptin receptor signaling and the regulation of mammalian physiology. Int J Obes 2008, 32(Suppl. 7):S8-S12.
78. Hardie D.G., Ross F.A., Hawley S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012, 13:251-262.
79. Segal R.A., Greenberg M.E. Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci 1996, 19:463-489.
80. Stefater M.A., Seeley R.J. Central nervous system nutrient signaling: the regulation of energy balance and the future of dietary therapies. Annu Rev Nutr 2010, 30:219-235.
81. Hayes M.R. Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects. Physiol Behav 2012, 106:413-416.
82. Turek V.F., Trevaskis J.L., Levin B.E., Dunn-Meynell A.A., Irani B., Gu G., et al. Mechanisms of amylin/leptin synergy in rodent models. Endocrinology 2010, 151:143-152.
83. Moon H.S., Chamberland J.P., Mantzoros C.S. Amylin and leptin activate overlapping signalling pathways in an additive manner in mouse GT1-7 hypothalamic, C(2)C(1)(2) muscle and AML12 liver cell lines. Diabetologia 2012, 55:215-225.
84. Potes C.S., Boyle C.N., Wookey P.J., Riediger T., Lutz T.A. Involvement of the extracellular signal-regulated kinase 1/2 signaling pathway in amylin's eating inhibitory effect. Am J Physiol Regul Integr Comp Physiol 2012, 302:R340-R351.
85. Lutz T.A., Del Prete E., Walzer B., Scharrer E. The histaminergic, but not the serotoninergic, system mediates amylin's anorectic effect. Peptides 1996, 17:1317-1322.
86. Mercer L.P., Kelley D.S., Humphries L.L., Dunn J.D. Manipulation of central nervous system histamine or histaminergic receptors (H1) affects food intake in rats. J Nutr 1994, 124:1029-1036.
87. Fukagawa K., Sakata T., Shiraishi T., Yoshimatsu H., Fujimoto K., Ookuma K., et al. Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus. Am J Physiol 1989, 256:R605-R611.
88. Mollet A., Lutz T.A., Meier S., Riediger T., Rushing P.A., Scharrer E. Histamine H1 receptors mediate the anorectic action of the pancreatic hormone amylin. Am J Physiol Regul Integr Comp Physiol 2001, 281:R1442-R1448.
89. Seth R., Terry D.E., Parrish B., Bhatt R., Overton J.M. Amylin-leptin coadministration stimulates central histaminergic signaling in rats. Brain Res 2012, 1442:15-24.
90. Armstrong D.M., Pickel V.M., Joh T.H., Reis D.J., Miller R.J. Immunocytochemical localization of catecholamine synthesizing enzymes and neuropeptides in area postrema and medial nucleus tractus solitarius of rat brain. J Comp Neurol 1981, 196:505-517.
91. Lutz T.A., Tschudy S., Mollet A., Geary N., Scharrer E. Dopamine D(2) receptors mediate amylin's acute satiety effect. Am J Physiol Regul Integr Comp Physiol 2001, 280:R1697-R1703.
92. De Mei C., Ramos M., Iitaka C., Borrelli E. Getting specialized: presynaptic and postsynaptic dopamine D2 receptors. Curr Opin Pharmacol 2009, 9:53-58.
93. Fallon J.H., Moore R.Y. Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J Comp Neurol 1978, 180:545-580.
94. Kalivas P.W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Brain Res Rev 1993, 18:75-113.
95. Flegal K.M., Carroll M.D., Ogden C.L., Curtin L.R. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
96. Obesity and Overweight: Fact Sheet [Accessed 1 Dec 2013]. http://www.who.int/mediacentre/factsheets/fs311/en/.
97. Inabnet W.B., Winegar D.A., Sherif B., Sarr M.G. Early outcomes of bariatric surgery in patients with metabolic syndrome: an analysis of the bariatric outcomes longitudinal database. J Am Coll Surg 2012, 214:550-556. [discussion 6-7].
98. Smith S.R., Blundell J.E., Burns C., Ellero C., Schroeder B.E., Kesty N.C., et al. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab 2007, 293:E620-E627.
99. Vetter M.L., Faulconbridge L.F., Webb V.L., Wadden T.A. Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol 2010, 6:578-588.
100. Greenway F.L., Whitehouse M.J., Guttadauria M., Anderson J.W., Atkinson R.L., Fujioka K., et al. Rational design of a combination medication for the treatment of obesity. Obesity 2009, 17:30-39.
101. Roth J.D., Roland B.L., Cole R.L., Trevaskis J.L., Weyer C., Koda J.E., et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 2008, 105:7257-7262.
102. Trevaskis J.L., Coffey T., Cole R., Lei C., Wittmer C., Walsh B., et al. Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology 2008, 149:5679-5687.
103. Bhavsar S., Watkins J., Young A. Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol Behav 1998, 64:557-561.
104. Lutz T.A., Del Prete E., Szabady M.M., Scharrer E. Attenuation of the anorectic effects of glucagon, cholecystokinin, and bombesin by the amylin receptor antagonist CGRP(8-37). Peptides 1996, 17:119-124.
105. Bello N.T., Kemm M.H., Ofeldt E.M., Moran T.H. Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates. Am J Physiol Regul Integr Comp Physiol 2010, 299:R945-R952.
106. Roth J.D., D'Souza L., Griffin P.S., Athanacio J., Trevaskis J.L., Nazarbaghi R., et al. Interactions of amylinergic and melanocortinergic systems in the control of food intake and body weight in rodents. Diabetes Obes Metab 2012, 14:608-615.
107. Lutz T.A. The interaction of amylin with other hormones in the control of eating. Diabetes Obes Metab 2013, 15:99-111.
108. Roth J.D., Trevaskis J.L., Turek V.F., Parkes D.G. "Weighing in" on synergy: preclinical research on neurohormonal anti-obesity combinations. Brain Res 2010, 1350:86-94.
109. Halaas J.L., Gajiwala K.S., Maffei M., Cohen S.L., Chait B.T., Rabinowitz D., et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269:543-546.
110. Gautron L., Elmquist J.K. Sixteen years and counting: an update on leptin in energy balance. J Clin Invest 2011, 121:2087-2093.
111. Jung C.H., Kim M.S. Molecular mechanisms of central leptin resistance in obesity. Arch Pharm Res 2013, 36:201-207.
112. Frederich R.C., Hamann A., Anderson S., Lollmann B., Lowell B.B., Flier J.S. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995, 1:1311-1314.
113. Boyle C.N., Rossier M.M., Lutz T.A. Influence of high-fat feeding, diet-induced obesity, and hyperamylinemia on the sensitivity to acute amylin. Physiol Behav 2011, 104:20-28.
114. Ravussin E., Smith S.R., Mitchell J.A., Shringarpure R., Shan K., Maier H., et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 2009, 17:1736-1743.
115. Chapman I., Parker B., Doran S., Feinle-Bisset C., Wishart J., Strobel S., et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005, 48:838-848.
116. Eiden S., Daniel C., Steinbrueck A., Schmidt I., Simon E. Salmon calcitonin-a potent inhibitor of food intake in states of impaired leptin signalling in laboratory rodents. J Physiol 2002, 541:1041-1048.
117. Osto M., Wielinga P.Y., Alder B., Walser N., Lutz T.A. Modulation of the satiating effect of amylin by central ghrelin, leptin and insulin. Physiol Behav 2007, 91:566-572.
118. Trevaskis J.L., Lei C., Koda J.E., Weyer C., Parkes D.G., Roth J.D. Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats. Obesity 2010, 18:21-26.
119. Geary N. Understanding synergy. Am J Physiol Endocrinol Metab 2013, 304:E237-E253.
120. Kanoski S.E., Zhao S., Guarnieri D.J., DiLeone R.J., Yan J., De Jonghe B.C., et al. Endogenous leptin receptor signaling in the medial nucleus tractus solitarius affects meal size and potentiates intestinal satiation signals. Am J Physiol Endocrinol Metab 2012, 303:E496-E503.
121. Moon H.S., Chamberland J.P., Diakopoulos K.N., Fiorenza C.G., Ziemke F., Schneider B., et al. Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans. Diabetes Care 2011, 34:132-138.
122. Banks A.S., Davis S.M., Bates S.H., Myers M.G. Activation of downstream signals by the long form of the leptin receptor. J Biol Chem 2000, 275:14563-14572.